BACKGROUND: A cohort study was undertaken to investigate the long-term oncological outcome, late adverse effects and quality of life (QOL) after treatment for rectal cancer. METHODS: This was an analysis of prospectively collected data from 268 consecutive patients with rectal carcinoma treated between 1995 and 1997 at the Department of Surgery, University Hospital Erlangen, Germany. RESULTS: Median follow-up was 8.8 years. The overall 10-year survival rate was 48.1 per cent. Of 219 patients who had a curative resection, 67 developed recurrent disease and 13 had second malignancies. Seventy patients had either a permanent stoma or a late adverse effect. Anorectal dysfunction and small bowel obstruction were significantly more common among patients who had multimodal treatment (P < 0.001 and P = 0.049 respectively). Analysis of QOL in 97 long-term survivors showed that receiving chemoradiotherapy, a permanent stoma and lower-third rectal carcinoma were associated with significantly worse outcomes on several measures. CONCLUSION: Late adverse effects and recurrences occurred in a significant number of patients during long-term follow-up. QOL varied according to tumour location and treatment type. Copyright (c) 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
BACKGROUND: A cohort study was undertaken to investigate the long-term oncological outcome, late adverse effects and quality of life (QOL) after treatment for rectal cancer. METHODS: This was an analysis of prospectively collected data from 268 consecutive patients with rectal carcinoma treated between 1995 and 1997 at the Department of Surgery, University Hospital Erlangen, Germany. RESULTS: Median follow-up was 8.8 years. The overall 10-year survival rate was 48.1 per cent. Of 219 patients who had a curative resection, 67 developed recurrent disease and 13 had second malignancies. Seventy patients had either a permanent stoma or a late adverse effect. Anorectal dysfunction and small bowel obstruction were significantly more common among patients who had multimodal treatment (P < 0.001 and P = 0.049 respectively). Analysis of QOL in 97 long-term survivors showed that receiving chemoradiotherapy, a permanent stoma and lower-third rectal carcinoma were associated with significantly worse outcomes on several measures. CONCLUSION: Late adverse effects and recurrences occurred in a significant number of patients during long-term follow-up. QOL varied according to tumour location and treatment type. Copyright (c) 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
Authors: Susanne Merkel; Klaus Weber; Maximilian Brunner; Justus Baecker; Abbas Agaimy; Jonas Göhl; Werner Hohenberger; Vera Schellerer; Robert Grützmann Journal: Int J Colorectal Dis Date: 2018-12-04 Impact factor: 2.571
Authors: Catherine E Mosher; Joseph G Winger; Barbara A Given; Paul R Helft; Bert H O'Neil Journal: Psychooncology Date: 2015-08-27 Impact factor: 3.894
Authors: T Sprenger; H Rothe; T Beissbarth; L-C Conradi; A Kauffels; K Homayounfar; C L Behnes; C Rödel; T Liersch; M Ghadimi Journal: Chirurg Date: 2016-07 Impact factor: 0.955
Authors: Dong Nyoung Son; Dong Jin Choi; Si Uk Woo; Jin Kim; Bo Ra Keom; Chul Hwan Kim; Se Jin Baek; Seon Hahn Kim Journal: World J Gastroenterol Date: 2013-01-28 Impact factor: 5.742
Authors: Marco E Allaix; Alberto Arezzo; Simone Arolfo; Mario Caldart; Fabrizio Rebecchi; Mario Morino Journal: J Gastrointest Surg Date: 2012-10-24 Impact factor: 3.452
Authors: Lisa J Herrinton; Andrea Altschuler; Carmit K McMullen; Joanna E Bulkley; Mark C Hornbrook; Virginia Sun; Christopher S Wendel; Marcia Grant; Carol M Baldwin; Wendy Demark-Wahnefried; Larissa K F Temple; Robert S Krouse Journal: CA Cancer J Clin Date: 2016-03-21 Impact factor: 508.702